Alice Soragni, PhD

Dr. Alice Soragni's lab focuses on two major and overlapping areas of research. First, they investigate how protein aggregation affects cancer development and progression, with a special focus on p53 aggregation. They exploit protein aggregation as a therapeutic target by designing peptides that interfere with the process.

Second, and in parallel, the lab focuses on developing clinically-relevant organoid models for cancer biology, as well as drug discovery and development applications. In particular, they establish tumor organoids from surgical specimens (patient-derived tumor organoids) and perform high-throughput drug screenings to individualize cancer therapy to each patient.

Nguyen HTL, Kohl E, Bade J, Eng SE, Tosevska A, Al Shihabi A, Tebon PJ, Hong JJ, Dry S, Boutros PC, Panossian A, Gosline SJC, Soragni A; A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.; Cell Reports Methods; 2024 

View in: PubMed

Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, Gonzalez AE, Sartini S, Murray GF, Nguyen HTL, Tavanaie N, Nguyen TL, Boutros PC, Teitell MA, Soragni A; Drug screening at single-organoid resolution via bioprinting and interferometry.; Nature Communications; 2023

View in: PubMed

Al Shihabi A, Davarifar A, Nguyen HTL, Tavanaie N, Nelson SD, Yanagawa J, Federman N, Bernthal N, Hornicek F, Soragni A; Personalized chordoma organoids for drug discovery studies.; Science Advances; 2022

View in: PubMed

Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, Huch M, Zeng YA, Wang Q, Yu H; Organoids.; Nature Reviews. Methods Primers; 2022

View in: PubMed